Skip to Main Content

Updated from 8 am EDT with new clinical trial data.

SAN DIEGO — Global Blood Therapeutics (GBT) said Monday that it had reached an agreement with the Food and Drug Administration for an accelerated approval submission of its experimental drug to treat sickle cell disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!